Citi downgraded Exact Sciences (EXAS) to Neutral from Buy with a price target of $105, up from $85, after it was announced Abbott Laboratories (ABT) will acquire the company for $105 per share. The firm sees minimal risk on any antitrust or regulatory issues and does not anticipate another bidder coming in, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS: